Industry
Biotechnology
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Loading...
Open
9.82
Mkt cap
568M
Volume
778K
High
9.84
P/E Ratio
-4.17
52-wk high
12.40
Low
9.03
Div yield
N/A
52-wk low
2.91
Portfolio Pulse from
November 06, 2024 | 6:30 pm
Portfolio Pulse from Benzinga Insights
October 28, 2024 | 4:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 28, 2024 | 4:08 pm
Portfolio Pulse from Benzinga Newsdesk
October 28, 2024 | 4:04 pm
Portfolio Pulse from Avi Kapoor
October 28, 2024 | 2:15 pm
Portfolio Pulse from Vandana Singh
October 28, 2024 | 12:46 pm
Portfolio Pulse from Benzinga Newsdesk
October 28, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Insights
October 28, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Insights
October 28, 2024 | 12:07 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.